Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc. for $680 million on April 30, 2024. As part of consideration $35 million paid in cash and $130 million upon the achievement of development and regulatory milestones and up to $515 million upon the achievement of certain sales-based milestones.

Zynerba Pharmaceuticals, Inc. completed the acquisition of Epygenix Therapeutics, Inc. on April 30, 2024.